A total of 948 shares of Moderna, Inc. have been acquired by Eisler Capital UK Ltd.

According to the company's most recent filing with the Securities and Exchange Commission, Eisler Capital UK Ltd made a new stake in Moderna, INC during the third quarter.

‍

The fund paid roughly 112,000 dollars to acquire 948 shares of firm stock, increasing its total expenditures to around 112,000 dollars.

‍

Some hedge funds have adjusted the proportion of their portfolios allocated to MRNA assets in recent months.

‍

RB Capital Management LLC acquired an extra 7.5% of the total number of shares issued by Moderna during the first three months of 2018. RB Capital Management LLC currently holds 2,267 shares of the company's stock valued at $390.000.

‍

This is due to the company's acquisition of an additional 158 shares during the most recent quarter.

‍

Throughout the first three months of 2018, Synovus Finance Corporation increased the proportion of Moderna shares it owned by 8.0%. The Synovus Finance Corporation.

‍

Now holds 4,049 shares of the company's stock after acquiring 300 additional shares during the most recent quarter.

‍

The current value of these shares on the market is $704,000.

‍

In the first quarter of 2018, Dimensional Fund Advisors LP added 5.1% more Moderna shares to its portfolio.

‍

Dimensional Fund Advisors LP now has 987,478 shares in the company, valued at $170,120,000, after acquiring 47,755 more shares during the most recent quarter.

‍

These shares were acquired in a transaction on the open market.

‍

Throughout the first three months of the year, Blair William & Co IL's ownership in Moderna shares increased by 12.4%. Blair William & Co, IL now has 15,611 shares of the company's stock in their portfolio following the acquisition of 1,724 more shares over the past quarter.

‍

According to the present market, the worth of these shares is $2,689,000.

‍

Lastly, during the first quarter of this year, Sei Investments Company boosted its ownership in Moderna shares by 41.4%. During the most recent fiscal quarter, Sei Investments Co acquired 58,160 shares of the company's stock by acquiring an additional 17,031 shares. These 58,160 shares are worth $10,019,000.

‍

Institutional investors hold 63.11% of the company's shares.

‍

Several experts specializing in equities research have lately written reports on publicly traded MRNA shares.

‍

In a study dated December 20 and made public by Piper Sandler, the price objective for Moderna was raised from $214.00 to $217.00.

‍

In addition, the firm awarded the company's shares an "overweight" rating. In a research note dated January 18, SVB Leerink raised Moderna from a "market perform" rating to a "outperform" one and boosted their price objective for the company from $102.00 to $111.00.

The price objective set to Moderna by Chardan Capital raised by $80.00, from $191.00 to $208.00, according to a research note released on January 18.

‍

The company assigned the stock a "neutral" rating, and the price target was increased by $8.00.

‍

The price target that Bank of America has set for Moderna has climbed from $160.00 to $182.00, according to a research report released on November 15. In a study published on January 25 and available to the public, Cowen raised their price estimate for Moderna from $130.00 to $150.00.

‍

In addition, they rated the firm the lowest possible grade, "market performs" Five equities research experts have suggested buying the stock, while the remaining five have recommended holding the stock.

‍

The firm is now classified as having a consensus "Moderate Buy" rating, as reported by Trade Algo.

‍

Its price target is estimated to have a consensus value of $193.23.

‍

In addition, the consensus price target for the company's stock is presently estimated to be $193.23.

‍

On Friday, the value of a share of MRNA stock declined by $7.80, reaching $164.51 by the day's conclusion.

‍

Significantly less shares were exchanged than the three-month average volume of 3,460,289 shares.

‍

The business has a price-to-earnings ratio of 6.23 and a beta value of 1.65.

‍

Currently, the market valuation of the corporation is $63.20 billion.

‍

The simple moving average of the stock price over the previous 50 trading days is $185.06, while the average for the last 200 trading days is $162.57.

‍

Moderna, INC's lowest price during the last year was $115.03, while its all-time high was $217.25.

‍

The company's debt-to-equity ratio is 0.05, while its current and quick ratios are 2.10 and 1.80, respectively.

‍

Over 0.05 is the debt-to-equity ratio of the company.

‍

The president of Moderna, Stephen Hoge, sold 245 shares of company stock on February 10. Additional developments may be viewed here.

‍

Total proceeds from selling the shares were $40,155.50, which works out to a price of $163.90 per share. Following the sale's conclusion, the firm's president currently owns 1,627,693 shares with an estimated value of $266,778,882.70 apiece.

‍

The selling of the shares generated a total income of $3,356,800.00. This is comparable to a price per share of $167.84. This leaves the director directly in control of 2,217,209 shares of the company with a total value of $372,136,358.56 following the successful completion of the transaction. One can access a document containing further details on the transaction by visiting the Securities and Exchange Commission (SEC) website. On the same day, Stephen Hoge, president of Moderna, sold 245 shares of the company's stock. On February 10, this deal was finalized.

‍

It was revealed that the shares were sold for an average price per share of $163.90, resulting in a total transaction volume of $40,155.50.

‍

As a direct result of the transaction, the company's president now directly owns 1,627,693 shares, which collectively have a value of $266,778,882.70.

‍

This area of the website may include disclosures associated with the transaction. Over the most recent fiscal quarter, corporate insiders sold 480,144 shares of company stock, resulting in a total income of $88,015,442.

‍

Corporate insiders own over 17.30% of the company's total shares of stock.

‍